HLB Therapeutics

Bio & Pharma PharmaResearch acquires TuringBio for digital therapeutics

PharmaResearch Co., a South Korean company specializing in regenerative medicine, announced on Wednesday that it acquired TuringBio, an AI-based dig...

Bio & Pharma Investors dump Korean biotech HLB stocks on FDA rejection

HLB Co. and its affiliate stocks tumbled on Friday on news that the South Korean biotech group’s highly anticipated new cancer treatment Rivoc...

IPOs Korean biotech Xcell Therapeutics eyes June IPO

South Korean biotech Xcell Therapeutics Inc., a developer of chemically defined media for in vitro cell culture, is aiming for a junior bourse Kosda...

Bio & Pharma Samsung invests in BrickBio in US

Samsung Group announced on Tuesday that its Life Science Fund has invested in the US-based antibody-drug conjugates (ADC) and gene therapy technol...

Bio & Pharma HLB gets global rights to Chinese liver cancer drug

South Korea’s HLB Therapeutics Co. on Tuesday said its US subsidiary Elevar Therapeutics has acquired the global rights excluding South Kore...

Bio & Pharma HLB signs with Japan's OSCL for exclusive supply of C-Trelin ingredient

South Korea's pharmaceutical company HLB Therapeutics Co. announced on Thursday that it has entered into a business agreement with Japan's Osaka Syn...

Bio & Pharma Celltrion to develop Humira biosimilar oral medication with US firm

South Korea's biopharmaceutical company Celltrion Inc. announced on Monday that it has signed a contract with the US biotech firm Rani Therapeutics ...

Bio & Pharma HLB submits new drug application to FDA for Rivoceranib liver cancer drug

HLB Co. announced on May 17 that it has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of Rivo...

Bio & Pharma Welt gets second digital therapeutic device approval in S. Korea

South Korea's Ministry of Food and Drug Safety announced on Wednesday that it has approved the cognitive therapy software "WELT-I" developed by We...

Bio & Pharma Vaxcell-bio's NK cell therapy wins therapeutic approval for liver cancer

South Korean anti-cancer immunotherapy company Vaxcell-Bio Therapeutics announced on Friday that its natural killer (NK) cell therapy, Vax-NK/HCC, h...

Bio & Pharma HLB starts Phase 3 clinical trials for ophthalmic disease treatment in US

South Korea's pharmaceutical company HLB Therapeutics Co. announced on Thursday that it has started patient administration of "RGN-259," a treatment...

Bio & Pharma HLB Cell develops organoid biomaterial based on human normal cells

HLB Cell, a subsidiary of HLB Life Science Co., which specializes in the development of cell therapy products, announced on April 4 that it succeede...

Bio & Pharma GC Biopharma to develop mRNA flu vaccine with Canadian pharma

South Korea's GC Biopharma Corp. announced on Thursday that it will start developing a flu vaccine based on messenger ribonucleic acid (mRNA).The dr...

Bio & Pharma AIMMED’s Somzz ushers in digital therapeutic device market in Korea

South Korea’s health and drug safety authority has cleared Somzz to treat patients with sleep disorders, a dynamic move that is expected to vi...

Bio & Pharma Hanall Biopharma invests in Interon Labs for brain disease treatments

South Korean pharmaceuticals firm Hanall Biopharma Co. is investing in Interon Laboratories, a US biotech firm that finds and develops treatments fo...

Bio & Pharma HLB’s Rivoceranib, Hengrui's Camrelizumab approved as combination therapy in China

South Korea's HLB Co. announced on Thursday that the combination therapy of its drug candidate rivoceranib and Jiangsu Hengrui Pharmaceuticals Co., ...

Bio & Pharma Celltrion develops oral antibody drug with US bio company

South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an or...

Bio & Pharma HLB confirms ophthalmic disease treatment in phase 3 clinical trials

South Korea’s biomedicine startup HLB Therapeutics Co. said on Monday that its Neurotrophic Keratopathy (NK) treatment RGN-259 proved effectiv...

Venture capital Korea’s big bio startups to launch $39 mn investment fund

South Korea’s four leading biotech firms plan to launch an investment fund of up to 50 billion won ($39 million) to support smaller domestic b...

Bio & Pharma HLB Therapeutics signs contract for COVID vaccine distribution rights

South Korea's pharmaceutical firm HLB Therapeutics Co. said on Monday that it has signed an agreement with the Korea Disease Control and Prevention ...

Bio & Pharma New drug developer Onconic Therapeutics raises $20 mn in Series B

South Korean drug developer Onconic Therapeutics, announced on Friday that it raised 26 billion won ($19.9 million) in Series B funding, with cumula...

Bio & Pharma MDimune signs research agreement with Australian National University

MDimune, a South Korean biotech company, said on Wednesday that it had signed an agreement with the Clear Vision Research (CVR) Lab, a research grou...

Bio & Pharma SK Discovery to control affiliates’ entire biotechnology business

SK Discovery Co., an intermediate holding company of South Korea’s third-largest conglomerate SK Group, will take charge of the entire biotech...

Bio & Pharma Samsung Biologics to double CDMO capacity with new plants worth $5.3 bn

Samsung Biologics Co., the world’s largest contract drugmaker, plans to double its manufacturing capacity by building four additional plants w...

Bio & Pharma Korean biotech firms fold COVID-19 therapeutics development businesses

A string of South Korean pharmaceutical and biotech companies are waving the white flag when it comes to developing COVID-19 treatments. As the...

Bio & Pharma KT, Hanmi-invested therapeutics maker Digital Pharm launched

Digital Pharm, jointly invested in by KT Corp. and Hanmi Pharmaceutical Co., held an official inauguration ceremony last week, the company announced...

Bio & Pharma SK invests in US digital healthcare firm Cala Health

South Korea's SK Biopharmaceuticals Co. has dipped its toes into the rapidly growing digital healthcare market by investing in Cala Health, a US-bas...

Mergers & Acquisitions Samsung buys $2.3 bn Bioepis stake from Biogen to end partnership

Samsung Biologics Co. is acquiring a nearly 50% stake in a biosimilar joint venture with Biogen Inc. from the US biotechnology company for $2.3 bill...

Pharmaceuticals Korean pharma joins global race in RNA therapeutics development

The field of ribonucleic acid (RNA) therapeutics, once considered an unexplored area, is now the most coveted sector in the global biotech industry....

Medicine Celltrion, Mirae to take largest stake in UK biotech firm

South Korean biosimilar maker Celltrion Inc. and Mirae Asset Group have agreed to an investment that will render them the top shareholder in Iksuda ...